Literature DB >> 9555782

Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Fibrate Consensus Group.

J C Fruchart1, H B Brewer, E Leitersdorf.   

Abstract

The hypolipidemic action of fibrates has recently been shown to involve the activation of peroxisome proliferator activated receptors establishing a molecular mechanism for this class of drugs. Increasing clinical trial evidence supports the efficacy of fibrates in the treatment of dyslipoproteinemias, particularly in patients with hypertriglyceridemia and low high-density lipoproteins.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9555782     DOI： 10.1016/s0002-9149(98)00010-1

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN： 0002-9149            Impact factor:   2.778


  29 in total

Review 1.  Toxicity of antilipidemic agents: facts and fictions.

Authors:  Antonios M Xydakis; Peter H Jones
Journal:  Curr Atheroscler Rep       Date:  2003-09       Impact factor: 5.113

Review 2.  Low high-density lipoprotein cholesterol: physiological background, clinical importance and drug treatment.

Authors:  Martin Hersberger; Arnold von Eckardstein
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 3.  Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection.

Authors:  Carl J Fichtenbaum; John G Gerber
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

4.  Gall bladder dysmotility: a risk factor for gall stone formation in hypertriglyceridaemia and reversal on triglyceride lowering therapy by bezafibrate and fish oil.

Authors:  I J A M Jonkers; A H M Smelt; M Ledeboer; M E Hollum; I Biemond; F Kuipers; F Stellaard; R Boverhof; A E Meinders; C H B W Lamers; A A M Masclee
Journal:  Gut       Date:  2003-01       Impact factor: 23.059

5.  Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017.

Authors:  Makoto Kinoshita; Koutaro Yokote; Hidenori Arai; Mami Iida; Yasushi Ishigaki; Shun Ishibashi; Seiji Umemoto; Genshi Egusa; Hirotoshi Ohmura; Tomonori Okamura; Shinji Kihara; Shinji Koba; Isao Saito; Tetsuo Shoji; Hiroyuki Daida; Kazuhisa Tsukamoto; Juno Deguchi; Seitaro Dohi; Kazushige Dobashi; Hirotoshi Hamaguchi; Masumi Hara; Takafumi Hiro; Sadatoshi Biro; Yoshio Fujioka; Chizuko Maruyama; Yoshihiro Miyamoto; Yoshitaka Murakami; Masayuki Yokode; Hiroshi Yoshida; Hiromi Rakugi; Akihiko Wakatsuki; Shizuya Yamashita
Journal:  J Atheroscler Thromb       Date:  2018-08-22       Impact factor: 4.928

Review 6.  Fibrates in the chemical action of daunorubicin.

Authors:  Ganesaratnam K Balendiran
Journal:  Curr Cancer Drug Targets       Date:  2009-05       Impact factor: 3.428

7.  Expression pattern of L-FABP gene in different tissues and its regulation of fat metabolism-related genes in duck.

Authors:  Jun He; Yong Tian; Jinjun Li; Junda Shen; Zhengrong Tao; Yan Fu; Dong Niu; Lizhi Lu
Journal:  Mol Biol Rep       Date:  2012-10-13       Impact factor: 2.316

8.  Anti-obesity effect of an isoflavone fatty acid ester on obese mice induced by high fat diet and its potential mechanism.

Authors:  Yao Yao; Xiao-Bo Li; Wei Zhao; Yan-Yan Zeng; Hong Shen; Hua Xiang; Hong Xiao
Journal:  Lipids Health Dis       Date:  2010-05-19       Impact factor: 3.876

9.  PPARα in Obesity: Sex Difference and Estrogen Involvement.

Authors:  Michung Yoon
Journal:  PPAR Res       Date:  2010-08-17       Impact factor: 4.964

10.  Retrospective comparison of the effectiveness of a fenofibrate 145 mg formulation compared with the standard 160 mg tablet.

Authors:  Michael H Davidson; Peter H Jones
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.